CoChat
Sign Up
Cited by 262Diabetes Treatment and ManagementPharmacovigilance and Adverse Drug ReactionsHeart Failure Treatment and Management

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Thiazolidinediones and Heart Failure

Singh, Sonal, Loke, Yoon K., Furberg, Curt D.·2007·Diabetes Care
DOI 10.2337/dc07-0141
Open this paper in CoChat — free account

Abstract

OBJECTIVE—Thiazolidinediones (TZDs) are known to increase the risk of heart failure in patients with type 2 diabetes. We aimed to evaluate the magnitude of the risk of heart failure with TZDs and classify this adverse effect under the novel dose-time-susceptibility system. RESEARCH DESIGN AND METHODS—Evidence from randomized trials, controlled observational studies, anecdotal case reports, case series, and spontaneous reports in the Canadian Drug Reaction Monitoring Program (CADRMP) was analyzed in a teleo-analysis. RESULTS—A random-effects meta-analysis of three randomized controlled trials showed an odds ratio (OR) of 2.1 (95% CI 1.08–4.08; P = 0.03) for the risk of heart failure in patients randomized to TZDs compared with placebo. Four observational studies revealed an OR of 1.55 (1.33–1.80; P < 0.00001) for heart failure with TZDs. A dose-time-susceptibility analysis of 28 published reports and 214 spontaneous reports from the CADRMP database showed that heart failure was more likely to occur after several months (with median treatment duration of 24 weeks after initiation of therapy). Heart failure equally occurred at high and low doses. The adverse reaction was not limited to the elderly, with 42 of 162 (26%) of the reported cases occurring in patients aged <60 years. CONCLUSIONS—Our teleo-analysis confirms the increased magnitude of the risk of heart failure with TZDs. We estimate the number needed to harm with TZDs to be ∼50 over 2.2 years. Existing guidelines and package inserts may have to be revised to incorporate these risk characteristics of TZDs.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc07-0141

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Cited by

Sorted by citations

Items 201–261 of 261

Related

See all

Metadata

Authors
Singh, S., Loke, Y. K., & Furberg, C. D.
Affiliations
  • Atrium Health Wake Forest Baptist (US)
  • University of East Anglia (GB)
  • Wake Forest University Health Sciences (US)
ORCID
Venue
Diabetes Care
Publisher
American Diabetes Association
Published
2007-08-01
Volume
30
Issue
8
Pages
2148-2153
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
DOI
10.2337/dc07-0141
OpenAlex
W1979369530
Cited by
262
References
31
Citations by year
2026: 3 · 2025: 4 · 2024: 11 · 2023: 9 · 2022: 9 · 2021: 12 · 2020: 13 · 2019: 11 · 2018: 11 · 2017: 6 · 2016: 12 · 2015: 14 · 2014: 15 · 2013: 19 · 2012: 18
FWCI
3.47
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
  • UEA Digital Repository (University of East Anglia) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
thiazolidinediones, heart failure, type 2 diabetes, adverse drug reactions, number needed to harm, drug safety, spontaneous adverse drug reports, drug labeling revision
MeSH terms
Diabetes Mellitus, Type 2, Diabetic Angiopathies, Disease Susceptibility, Heart Failure, Humans, Hypoglycemic Agents, Odds Ratio, Randomized Controlled Trials as Topic, Thiazolidinediones

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review